Veröffentlichungsdatum: 8 September 2020
Projektträger – zwischengeschaltetes Finanzinstitut
Research and Development (R&D) financing for Erydel, an Italian biotech Company that designs and produce Erythrocyte-based drug delivery systems for the treatment of rare/orphan diseases, such as Ataxia Telangiectasia.
The proposed transaction will support R&D investments required to bring ERYDEX program to market, addressing a highly unmet medical need that represents Ataxia Telangiectasia (a rare neurological disease) in a growing patient population. In addition, it will support the company's development of its drug pipeline; preserving and cultivating highly skilled employment opportunities.
Please no communication before Signature and coordination with the client. This loan is part of the European Growth Finance Facility (EGFF) programme developed under EFSI
- Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 30 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 64 million
The promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending 2011/92/EU. Full environmental details will be verified during appraisal of the project.
The Promoter is a private company, not operating in the utilities sector, and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Unterzeichnet - 24/07/2020
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).